Results 21 to 30 of about 2,667 (188)

Population PK-PD Modeling of Danicopan Add-On Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab or Eculizumab. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Danicopan is a first‐in‐class orally administered complement factor D inhibitor, approved as an add‐on therapy to ravulizumab or eculizumab for the treatment of clinically significant extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Chen J, Yang F, Li H, Pradhan R, Ortiz S.   +4 more
europepmc   +2 more sources

Successful management of unstable angina in a ravulizumab-treated patient with paroxysmal nocturnal hemoglobinuria [PDF]

, 2022
Ravulizumab is an anti-C5 antibody approved for treating paroxysmal nocturnal hemoglobinuria (PNH). In August 2019, a 77-year-old Japanese man with PNH, who had been on ravulizumab treatment for 2 years, was hospitalized for chest discomfort and malaise.
Fukatsu, Masahiko, Harada, Kayo, Ikezoe, Takayuki, Kimura, Satoshi, Mori, Hirotaka, Ohkawara, Hiroshi, Oikawa, Masayoshi, Sano, Takahiro, Shichishima, Tsutomu, Takahashi, Hiroshi, Takeishi, Yasuchika, 七島, 勉, 佐野, 隆浩, 原田, 佳代, 及川, 雅啓, 大河原, 浩, 木村, 哲, 森, 博隆, 池添, 隆之, 深津, 真彦, 竹石, 恭知, 高橋, 裕志   +21 more
core   +1 more source

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults [PDF]

, 2021
Hemolytic uremic syndrome; Kidney failure; RavulizumabSíndrome hemolítico urémico; Insuficiencia renal; RavulizumabSíndrome hemolític urèmic; Insuficiència renal; RavulizumabIntroduction Atypical hemolytic uremic syndrome (aHUS) is a rare, complex ...
Ariceta Iraola, Gema, Barbour, Thomas, Cataland, Spero, Garlo, Katherine, Heyne, Nils, Scully, Marie   +5 more
core   +1 more source

The potential of individualized dosing of ravulizumab to improve patient-friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs [PDF]

, 2021
Contains fulltext : 237767.pdf (Publisher’s version ) (Open Access)Ravulizumab is a very expensive complement C5-inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria, with a fixed-dosing interval of 8 weeks.
Avest, M. ter, Blijlevens, N.M.A., Burger, D.M., Heine, R. ter, Kar, N.C.A.J. van de, Kievit, W., Langemeijer, S.M.C., Schols, S.E.M.   +7 more
core   +1 more source

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Neurology and Therapy, 2023
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare ...
Tuan Vu, Andreas Meisel, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Rasha Aguzzi, Ahmed Enayetallah, Kathleen N. Beasley, Nishi Rampal, James F. Howard   +9 more
doaj   +1 more source

Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United StatesPlain language summary

Kidney Medicine, 2023
Rationale and Objective: Ravulizumab and eculizumab have shown efficacy for the treatment of atypical hemolytic uremic syndrome (aHUS), but real-world evidence for ravulizumab is limited owing to its more recent approval.
Yan Wang, Imad Al-Dakkak, Katherine Garlo, Moh-Lim Ong, Ioannis Tomazos, Arash Mahajerin   +5 more
doaj   +1 more source

One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study

Therapeutic Advances in Hematology, 2020
Background: Ravulizumab, the only long-acting complement C5 inhibitor for adults with paroxysmal nocturnal hemoglobinuria (PNH), demonstrated non-inferiority to eculizumab after 26 weeks of treatment in complement inhibitor-naïve patients during a phase ...
Hubert Schrezenmeier, Austin Kulasekararaj, Lindsay Mitchell, Flore Sicre de Fontbrune, Timothy Devos, Shinichiro Okamoto, Richard Wells, Scott T. Rottinghaus, Peng Liu, Stephan Ortiz, Jong Wook Lee, Gérard Socié   +11 more
doaj   +1 more source

Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome. [PDF]

, 2023
Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening form of thrombotic microangiopathy (TMA) which is caused by dysregulation of the alternative complement pathway (AP). Complement inhibition is an effective therapeutic
Bagga, A., Charney, A., Chen, C.W., Dahlke, M., Fakhouri, F., Greenbaum, L.A., Karki, R.G., Kavanagh, D., Vasudevan, S.   +8 more
core   +1 more source

Complement Mediated Hemolytic Anemias in the COVID-19 Era : Case Series and Review of the Literature [PDF]

, 2021
The complex pathophysiologic interplay between SARS-CoV-2 infection and complement activation is the subject of active investigation. It is clinically mirrored by the occurrence of exacerbations of complement mediated diseases during COVID-19 infection ...
Barcellini W., Bellani V., Fattizzo B., Kulasekararaj A. G., Pasquale R.   +4 more
core   +1 more source

Ravulizumab (Ultomiris)

Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire   +2 more sources